Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes

Kazama, Hirohito; Usui, S; Okazaki, M; Hosoi, T; Ito, H; Orimo, H

« Previous Next »Diabetes Research and Clinical Practice
Volume 59, Issue 3 , Pages 181-189, March 2003

Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes

Hirohito Kazama
- Department of Endocrinology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan
- Corresponding author. Present address: Department of Internal Medicine, Kikkoman General Hospital, 100 Miyazaki, Noda-city, Chiba 278-0005, Japan. Tel.: +81-47-12-35911; fax: +81-47-12-35920
S Usui
- Department of Biochemistry and Biophysics, Graduate School of Allied Health Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-0034, Japan
M Okazaki
- Laboratory of Chemistry, College of Liberal Arts and Sciences, Tokyo Medical and Dental University, 2-8-30 Kohnodai, Ichikawa-shi, Chiba 272-0827, Japan
T Hosoi
- Department of Endocrinology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan
H Ito
- Department of Endocrinology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan
H Orimo
- Department of Endocrinology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan

Received 25 February 2002; received in revised form 11 September 2002; accepted 1 October 2002.

Abstract

The effects of bezafibrate and pravastatin on remnant-like lipoprotein particles (RLPs) and lipoprotein subclasses were compared in type 2 diabetes. Bezafibrate (400 mg/day) and pravastatin (10 mg/day) were given to 27 Japanese diabetics in a randomized crossover design. RLP cholesterol (RLP-C) and RLP triglyceride (RLP-TG) were measured by an immunoseparation technique. LDL and HDL were separated each into three subclasses (large, medium, small) and their cholesterol (C) contents were measured by an HPLC method. RLP-C was reduced more effectively by pravastatin (bezafibrate −16.0% vs. pravastatin −40.6%, P<0.05), whereas RLP-TG was reduced more effectively by bezafibrate (−55.2% vs. −35.0%, P<0.05). Further, pravastatin decreased large and small LDL-C levels equally (large; −23.6%; medium; −17.2%, small; −21.0%), while bezafibrate produced a relatively larger reduction in small LDL-C (−12.1; −16.9; −21.5%). Whereas bezafibrate significantly decreased large HDL-C and increased medium and small HDL-C (−49.6; 34.1; 35.8%), pravastatin significantly increased only medium HDL-C (5.2; 9.4; 5.9%). Bezafibrate reduced RLP-C and RLP-TG more effectively in patients with high TG levels, whereas pravastatin's effect was not markedly influenced by the initial TG level. Thus measurements of RLP-C, RLP-TG, and HPLC subclasses revealed that bezafibrate and pravastatin differently influence the lipoprotein status in type 2 diabetes.

Keywords: Diabetes mellitus, Remnant-like lipoprotein particles, Lipoprotein subclass, Bezafibrate, Pravastatin, High performance liquid chromatography